Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance:
Copyright © 2016. Georg Thieme Verlag KG. All rights reserved. Hypertension is a significant comorbidity associated with insulin resistance and type-2 diabetes. Limited evidence show that ursodeoxycholic acid (UDCA) has some anti-hypertensive effects. However, the potential effect of UDCA on hyperte...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
MVS Medizinverlage Stuttgart
2016
|
| Online Access: | http://hdl.handle.net/20.500.11937/5188 |
| _version_ | 1848744725736062976 |
|---|---|
| author | Al-Salami, Hani Mamo, John Mooranian, Armin Negrulj, Rebecca Lam, Virginie Elahy, Mina Takechi, Ryu |
| author_facet | Al-Salami, Hani Mamo, John Mooranian, Armin Negrulj, Rebecca Lam, Virginie Elahy, Mina Takechi, Ryu |
| author_sort | Al-Salami, Hani |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Copyright © 2016. Georg Thieme Verlag KG. All rights reserved. Hypertension is a significant comorbidity associated with insulin resistance and type-2 diabetes. Limited evidence show that ursodeoxycholic acid (UDCA) has some anti-hypertensive effects. However, the potential effect of UDCA on hypertension induced by type-2 diabetic insulin resistance has not been reported. In C57Bl6 wild-type mice, insulin resistance was induced by the chronic ingestion of diet enriched in fat and fructose (HFF). HFF mice were randomized to treatment with UDCA or candersartan incorporated into the diet to achieve an ingested dose of approximately 70 mg/kg/day of UDCA or 3 mg/kg/day respectively. Systolic and diastolic blood pressure were measured with tail-cuff method. At 4 weeks of dietary treatment systolic and diastolic blood pressure were comparable in HFF and low-fat (LF) control mice. Co-administration of candesartan at 4 weeks significantly decreased systolic and diastolic blood pressure, UDCA showed no anti-hypertensive effect at 4 weeks. At 24 weeks of dietary intervention, HFF fed mice had substantially elevated systolic blood pressure compared to LF controls. The provision of UDCA substantially attenuated the dietary HFF induced increase in systolic blood pressure concomitant with significantly lower plasma angiotensin II. The anti-hypertensive effect of UDCA in HFF mice was comparable to candesartan. The data suggests that long term supplementation of UDCA effectively lowers hypertension in a dietary induced model of type-2 diabetic insulin resistance. |
| first_indexed | 2025-11-14T06:06:02Z |
| format | Journal Article |
| id | curtin-20.500.11937-5188 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T06:06:02Z |
| publishDate | 2016 |
| publisher | MVS Medizinverlage Stuttgart |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-51882017-09-13T14:39:53Z Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance: Al-Salami, Hani Mamo, John Mooranian, Armin Negrulj, Rebecca Lam, Virginie Elahy, Mina Takechi, Ryu Copyright © 2016. Georg Thieme Verlag KG. All rights reserved. Hypertension is a significant comorbidity associated with insulin resistance and type-2 diabetes. Limited evidence show that ursodeoxycholic acid (UDCA) has some anti-hypertensive effects. However, the potential effect of UDCA on hypertension induced by type-2 diabetic insulin resistance has not been reported. In C57Bl6 wild-type mice, insulin resistance was induced by the chronic ingestion of diet enriched in fat and fructose (HFF). HFF mice were randomized to treatment with UDCA or candersartan incorporated into the diet to achieve an ingested dose of approximately 70 mg/kg/day of UDCA or 3 mg/kg/day respectively. Systolic and diastolic blood pressure were measured with tail-cuff method. At 4 weeks of dietary treatment systolic and diastolic blood pressure were comparable in HFF and low-fat (LF) control mice. Co-administration of candesartan at 4 weeks significantly decreased systolic and diastolic blood pressure, UDCA showed no anti-hypertensive effect at 4 weeks. At 24 weeks of dietary intervention, HFF fed mice had substantially elevated systolic blood pressure compared to LF controls. The provision of UDCA substantially attenuated the dietary HFF induced increase in systolic blood pressure concomitant with significantly lower plasma angiotensin II. The anti-hypertensive effect of UDCA in HFF mice was comparable to candesartan. The data suggests that long term supplementation of UDCA effectively lowers hypertension in a dietary induced model of type-2 diabetic insulin resistance. 2016 Journal Article http://hdl.handle.net/20.500.11937/5188 10.1055/s-0042-106084 MVS Medizinverlage Stuttgart restricted |
| spellingShingle | Al-Salami, Hani Mamo, John Mooranian, Armin Negrulj, Rebecca Lam, Virginie Elahy, Mina Takechi, Ryu Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance: |
| title | Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance: |
| title_full | Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance: |
| title_fullStr | Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance: |
| title_full_unstemmed | Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance: |
| title_short | Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance: |
| title_sort | long-term supplementation of microencapsulated ursodeoxycholic acid prevents hypertension in a mouse model of insulin resistance: |
| url | http://hdl.handle.net/20.500.11937/5188 |